ClinicalTrials.gg
CompletedNCT07011797Updated May 28, 2026

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

A Phase 2 interventional study of CX11 and Placebo in Obesity, sponsored by Corxel Pharmaceuticals. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Corxel Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study:

  • To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo.
  • To compare the changes of effects in weight and weight-related indicators at the visit time points.
  • To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants.
  • To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants.

Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.

02

Conditions studied

  • Obesity

Keywords

  • Overweight/Obese participants
  • Changes in weight and weight related indicators
  • Safety and Tolerability of IP
  • Efficacy, Safety, Tolerability and PK characteristic of different doses
  • Percentage change in weight
  • Body weight reduction
  • Change in waist circumference
  • Change in Body Mass Index
  • Pharmacokinetic analysis
  • Columbia-Suicide Severity Rating Scale
  • Patient Health Questionnaire-9
  • Weight loss
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 250 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Corxel Pharmaceuticals is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who meet all of the following criteria will be eligible to participate in this study:

  • Between 18 and 75 years old. Both men and women can participate, but women may make up to 70% of the participants.
  • of 30 or higher, or a BMI between 27 and 30 with at least one related health condition such as prediabetes, high blood pressure, abnormal cholesterol levels, fatty liver, or sleep apnea due to being overweight.
  • level below 6.5% and fasting blood sugar levels below 126 mg/dL.
  • Have tried and failed to lose weight through diet and exercise at least once before the study and must have had a stable body weight (less than a 5% change) in the 90 days before the study.
  • Participants and their partners must not plan to become pregnant or donate sperm/eggs during the study and for 90 days after. They must agree to use effective for at least 6 months prior to screening and continue their chosen contraception method throughout the study. Women who could become pregnant must have a negative pregnancy test 24 hours before the first dose of study drug.
  • Willing to maintain a stable diet and exercise routine during the study and keep a diary of their activities.
  • Understand the study procedures, be willing to follow the study rules strictly, and sign a consent form voluntarily.

Exclusion criteria

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from this study:

  • Known or suspected to GLP-1 receptor agonists or similar products.
  • Took part in another clinical study and received treatment within the last 90 days or within 5 drug elimination half-lives.
  • Any type of diabetes.
  • Obesity caused by hormonal or genetic issues such as thyroid problems, Cushing's syndrome, or other specific conditions.
  • Have had or plan to have obesity treatment surgery or use weight loss devices, with some exceptions if done over a year ago.
  • Have used certain medications or therapies for weight loss or conditions affecting weight, including GLP-1 receptor agonists and other related drugs, within the last 90 days.
  • Recent serious heart problems, uncontrolled high blood pressure, or certain abnormalities.
  • History of pancreatitis, gallbladder disease (except for those treated with cholecystectomy), or evidence of hypothyroidism (except for participants who have normal thyroid function at screening and have been on a stable dose thyroid replacement for at least 90 days and are expected to maintain a stable dose during the study) or hyperthyroidism or thyrotoxicosis.
  • History of cancer in the last 5 years, except for localized basal or squamous skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer.
  • Serious gastrointestinal diseases or surgeries that affect drug absorption.
  • Active liver disease, excluding nonalcoholic fatty liver disease.
  • Other serious health conditions that could increase study risk or make participation inappropriate, including certain psychiatric disorders.
  • Recent history of unexplained fainting or family history of long syndrome or sudden death.
  • History of organ transplant or severe diseases.
  • Had major surgery within the last 6 months or plan to have surgery soon.
  • Significant abnormalities in kidney function, liver enzymes, blood tests, or other specified lab results.
  • Positive for , , or .
  • Donated blood, lost a lot of blood, or received a transfusion in the last 90 days.
  • Exceed weekly alcohol intake limits or have a history of drug abuse (including cannabis, its derivatives, or any cannabis-containing products; except for prescribed drug for medical purpose).
  • Women who are pregnant or breastfeeding.
  • Any other disease, condition, or medication that the investigator believes would interfere with the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
250 participants (actual)

Study arms

  • Placebo comparator
    Placebo group

    Other: Placebo

  • Experimental
    120 mg group

    Drug: CX11

  • Experimental
    160 mg group

    Drug: CX11

  • Experimental
    200 mg fast titration group

    Drug: CX11

  • Experimental
    200 mg slow titration group

    Drug: CX11

Interventions

  • DrugCX11

    CX11 tablets administered orally once daily (QD) with meals

    Also known as: VCT220

  • OtherPlacebo

    Matching placebo tablets administered orally once daily (QD) with meals

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline

    Time frame: At Week 26

Secondary outcomes

  1. Proportion of participants achieving ≥ 5% body weight reduction from baseline

    Time frame: At Week 26

  2. Percentage change in body weight from baseline

    Time frame: At Week 36

  3. Proportion of participants achieving ≥ 5% body weight reduction from baseline

    Time frame: At Week 36

  4. Proportion of participants achieving ≥ 10% body weight reduction from baseline

    Time frame: At Week 26 and Week 36

  5. Change in body weight from baseline

    Time frame: At Week 26 and Week 36

  6. Change in waist circumference from baseline

    Time frame: At Week 26 and Week 36

  7. Change in body mass index (BMI) from baseline

    Time frame: At Week 26 and Week 36

  8. Number of adverse events (AEs)

    Time frame: Study duration, approximately 38 weeks

  9. Number of treatment-emergent adverse events (TEAEs)

    Time frame: Study duration, approximately 38 weeks

  10. Number of AE of special interest (AESI)

    Time frame: Study duration, approximately 38 weeks

  11. Number of serious adverse events (SAEs)

    Time frame: Study duration, approximately 38 weeks

  12. Columbia-Suicide Severity Rating Scale [C-SSRS]

    Higher scores on the C-SSRS indicate a worse outcome, as they reflect greater severity of suicidal ideation and behavior. The scale begins at 0 and there is no single maximum value as the scale consists of multiple items that assess different aspects of suicidal ideation and behavior. Each item is scored individually, and the overall assessment is based on the combination of responses.

    Time frame: At Day 1, Week 12, Week 26, Week 36 or at early termination (ET)

  13. Patient Health Questionnaire-9 [PHQ-9]

    Higher scores on the PHQ-9 indicate a worse outcome, as they reflect more severe depression. The minimum score of the PHQ-9 is 0 and the maximum score of the PHQ-9 is 27.

    Time frame: At Day 1, Week 12, Week 26, Week 36 or at ET

  14. Maximum steady-state plasma concentration (Cmax,ss)

    Time frame: Day 1 through Week 26

  15. Minimum steady-state plasma concentration (Cmin,ss)

    Time frame: Day 1 through Week 26

  16. Time to maximum steady-state plasma concentration (Tmax,ss)

    Time frame: Day 1 through Week 26

  17. Area under the curve from 0 h to the time of the last quantifiable concentration (AUC0-last,ss)

    Time frame: Day 1 through Week 26

  18. Area under the concentration-time curve over the dosing interval (AUC0-tau)

    Time frame: Day 1 through Week 26

07

Study locations

17 sites
  • AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central
    Phoenix, Arizona 85020-4327, United States
  • 310 Clinical Research - Alliance Clinical - Los Angeles
    Inglewood, California 90301, United States
  • Acclaim Clinical Research - Alliance Clinical - San Diego
    San Diego, California 92120, United States
  • Angels Clinical Research Institute - Miami
    Doral, Florida 33122-1713, United States
  • AES - DRS - Optimal Research Florida - Melbourne
    Melbourne, Florida 32934-8172, United States
  • Angels Clinical Research Institute
    Miami, Florida 33126, United States
  • Palm Springs Community Health Center
    Miami Lakes, Florida 33014-2266, United States
  • Oceanic Research Group, LLC
    North Miami Beach, Florida 33169, United States
  • Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS
    Savannah, Georgia 31406-3928, United States
  • Privia Medical Group Georgia, LLC - Thomasville - Javara - PPDS
    Thomasville, Georgia 31792-6618, United States
  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS
    Valparaiso, Indiana 46383, United States
  • Mankato Clinic - East Main Street - Javara - PPDS
    Mankato, Minnesota 56001, United States
  • Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS
    Cincinnati, Ohio 45246-2316, United States
  • Velocity Clinical Research - Dallas - PPDS
    Dallas, Texas 75230, United States
  • Epic Clinical Research - Alliance Clinical - Lewisville
    Lewisville, Texas 75057, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - San Antonio
    San Antonio, Texas 78229, United States
  • Flourish Research - San Antonio - PPDS
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Mar 2026, 9 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 10, 2025
StartActual
Jun 17, 2025
Primary completionActual
Mar 23, 2026
CompletionActual
Apr 9, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07011797
Lead sponsor
Corxel Pharmaceuticals
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Jun 17, 2025
Primary completion
Mar 23, 2026
Completion
Apr 9, 2026
Last update
May 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CX11

Start the discussion